Review





Similar Products

94
MedChemExpress dpp4 inhibitor sitagliptin
Analysis of ligands and receptors in senescent and receiving cells. (A) Schematic depicting BulkSignalR pipeline which uses known ligand‐receptor interactions and affected downstream pathways to analyze their activation based on our bulk RNAseq data from DMSO and BrdU treated human cell lines (created with BioRender). (B) Venn diagram showing the number of receptors inferred from BulkSignalR to be activated across each of the five human cell types. Three receptors were identified in common between astrocytes (purple), endothelial cells (pink), and microglia (yellow) which were the cell types shown (Figure ) to be capable of receiving senescence signals and becoming SA β‐gal positive: CXCR7, KREMEN2, and GIPR. Only CXCR7 was expressed in the cell types capable of entering secondary senescence (astrocytes, endothelial cells, microglia) (Figure , Figure ). (C) TPM expression values of CXCR7 , its ligand CXCL12 , and <t>DPP4</t> which cleaves and inactivates CXCL12 in DMSO (gray) and BrdU (red) treated cell lines ( n = 3 replicates). (D) Schematic of the four selected SASP inhibitors mechanisms of action: Bindarit is a CCL2 synthesis inhibitor which prevents p65 activation of the CCL2 gene at the promoter region, ISO‐1 is a MIF antagonist, ACT‐1004‐1239 is a CXCR7 antagonist, and Sitagliptin inhibits DPP4 preventing its action of cleaving and inactivating CXCL12 (created with BioRender). Data were analyzed by two‐way ANOVA with Tukey's multiple comparisons test (C). All graphs show mean with error bars depicting standard deviation (ns, p > 0.05, ** p < 0.01, *** p < 0.001).
Dpp4 Inhibitor Sitagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pmc13476760-321-2-5
Average 94 stars, based on 1 article reviews
dpp4 inhibitor sitagliptin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
TargetMol sitagliptin
Analysis of ligands and receptors in senescent and receiving cells. (A) Schematic depicting BulkSignalR pipeline which uses known ligand‐receptor interactions and affected downstream pathways to analyze their activation based on our bulk RNAseq data from DMSO and BrdU treated human cell lines (created with BioRender). (B) Venn diagram showing the number of receptors inferred from BulkSignalR to be activated across each of the five human cell types. Three receptors were identified in common between astrocytes (purple), endothelial cells (pink), and microglia (yellow) which were the cell types shown (Figure ) to be capable of receiving senescence signals and becoming SA β‐gal positive: CXCR7, KREMEN2, and GIPR. Only CXCR7 was expressed in the cell types capable of entering secondary senescence (astrocytes, endothelial cells, microglia) (Figure , Figure ). (C) TPM expression values of CXCR7 , its ligand CXCL12 , and <t>DPP4</t> which cleaves and inactivates CXCL12 in DMSO (gray) and BrdU (red) treated cell lines ( n = 3 replicates). (D) Schematic of the four selected SASP inhibitors mechanisms of action: Bindarit is a CCL2 synthesis inhibitor which prevents p65 activation of the CCL2 gene at the promoter region, ISO‐1 is a MIF antagonist, ACT‐1004‐1239 is a CXCR7 antagonist, and Sitagliptin inhibits DPP4 preventing its action of cleaving and inactivating CXCL12 (created with BioRender). Data were analyzed by two‐way ANOVA with Tukey's multiple comparisons test (C). All graphs show mean with error bars depicting standard deviation (ns, p > 0.05, ** p < 0.01, *** p < 0.001).
Sitagliptin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pm41912581-562-5-6
Average 94 stars, based on 1 article reviews
sitagliptin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
MedChemExpress blood
Analysis of ligands and receptors in senescent and receiving cells. (A) Schematic depicting BulkSignalR pipeline which uses known ligand‐receptor interactions and affected downstream pathways to analyze their activation based on our bulk RNAseq data from DMSO and BrdU treated human cell lines (created with BioRender). (B) Venn diagram showing the number of receptors inferred from BulkSignalR to be activated across each of the five human cell types. Three receptors were identified in common between astrocytes (purple), endothelial cells (pink), and microglia (yellow) which were the cell types shown (Figure ) to be capable of receiving senescence signals and becoming SA β‐gal positive: CXCR7, KREMEN2, and GIPR. Only CXCR7 was expressed in the cell types capable of entering secondary senescence (astrocytes, endothelial cells, microglia) (Figure , Figure ). (C) TPM expression values of CXCR7 , its ligand CXCL12 , and <t>DPP4</t> which cleaves and inactivates CXCL12 in DMSO (gray) and BrdU (red) treated cell lines ( n = 3 replicates). (D) Schematic of the four selected SASP inhibitors mechanisms of action: Bindarit is a CCL2 synthesis inhibitor which prevents p65 activation of the CCL2 gene at the promoter region, ISO‐1 is a MIF antagonist, ACT‐1004‐1239 is a CXCR7 antagonist, and Sitagliptin inhibits DPP4 preventing its action of cleaving and inactivating CXCL12 (created with BioRender). Data were analyzed by two‐way ANOVA with Tukey's multiple comparisons test (C). All graphs show mean with error bars depicting standard deviation (ns, p > 0.05, ** p < 0.01, *** p < 0.001).
Blood, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pm42587154-536-4-17
Average 94 stars, based on 1 article reviews
blood - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
MedChemExpress sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Sitagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pmc13422273-57-14-25
Average 94 stars, based on 1 article reviews
sitagliptin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

86
Hikma Inc pure sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Pure Sitagliptin, supplied by Hikma Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/pure+sitagliptin/pm42162103-57-0-7
Average 86 stars, based on 1 article reviews
pure sitagliptin - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Diabetology sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Sitagliptin, supplied by Diabetology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/sitagliptin/pm42070662-76-23-9
Average 86 stars, based on 1 article reviews
sitagliptin - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Macklin Inc standard drugs sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Standard Drugs Sitagliptin, supplied by Macklin Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/drugs+sitagliptin+standard/pmc13125983-250-0-11
Average 86 stars, based on 1 article reviews
standard drugs sitagliptin - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

94
MedChemExpress dpp 4 inhibitor sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Dpp 4 Inhibitor Sitagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pm41990259-273-23-27
Average 94 stars, based on 1 article reviews
dpp 4 inhibitor sitagliptin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
TargetMol puerarin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Puerarin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/Sitagliptin/pm41912581-562-11-12
Average 94 stars, based on 1 article reviews
puerarin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

86
Merck & Co dipeptidyl peptidase 4 dpp 4 inhibitor sitagliptin
Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or <t>sitagliptin</t> (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001
Dipeptidyl Peptidase 4 Dpp 4 Inhibitor Sitagliptin, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sitagliptin/dpp4+inhibitor/pm41906117-193-5-10
Average 86 stars, based on 1 article reviews
dipeptidyl peptidase 4 dpp 4 inhibitor sitagliptin - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Analysis of ligands and receptors in senescent and receiving cells. (A) Schematic depicting BulkSignalR pipeline which uses known ligand‐receptor interactions and affected downstream pathways to analyze their activation based on our bulk RNAseq data from DMSO and BrdU treated human cell lines (created with BioRender). (B) Venn diagram showing the number of receptors inferred from BulkSignalR to be activated across each of the five human cell types. Three receptors were identified in common between astrocytes (purple), endothelial cells (pink), and microglia (yellow) which were the cell types shown (Figure ) to be capable of receiving senescence signals and becoming SA β‐gal positive: CXCR7, KREMEN2, and GIPR. Only CXCR7 was expressed in the cell types capable of entering secondary senescence (astrocytes, endothelial cells, microglia) (Figure , Figure ). (C) TPM expression values of CXCR7 , its ligand CXCL12 , and DPP4 which cleaves and inactivates CXCL12 in DMSO (gray) and BrdU (red) treated cell lines ( n = 3 replicates). (D) Schematic of the four selected SASP inhibitors mechanisms of action: Bindarit is a CCL2 synthesis inhibitor which prevents p65 activation of the CCL2 gene at the promoter region, ISO‐1 is a MIF antagonist, ACT‐1004‐1239 is a CXCR7 antagonist, and Sitagliptin inhibits DPP4 preventing its action of cleaving and inactivating CXCL12 (created with BioRender). Data were analyzed by two‐way ANOVA with Tukey's multiple comparisons test (C). All graphs show mean with error bars depicting standard deviation (ns, p > 0.05, ** p < 0.01, *** p < 0.001).

Journal: Aging Cell

Article Title: Characterizing the SASP ‐Dependent Paracrine Spreading of Senescence Between Human Brain Cell Types

doi: 10.1111/acel.70673

Figure Lengend Snippet: Analysis of ligands and receptors in senescent and receiving cells. (A) Schematic depicting BulkSignalR pipeline which uses known ligand‐receptor interactions and affected downstream pathways to analyze their activation based on our bulk RNAseq data from DMSO and BrdU treated human cell lines (created with BioRender). (B) Venn diagram showing the number of receptors inferred from BulkSignalR to be activated across each of the five human cell types. Three receptors were identified in common between astrocytes (purple), endothelial cells (pink), and microglia (yellow) which were the cell types shown (Figure ) to be capable of receiving senescence signals and becoming SA β‐gal positive: CXCR7, KREMEN2, and GIPR. Only CXCR7 was expressed in the cell types capable of entering secondary senescence (astrocytes, endothelial cells, microglia) (Figure , Figure ). (C) TPM expression values of CXCR7 , its ligand CXCL12 , and DPP4 which cleaves and inactivates CXCL12 in DMSO (gray) and BrdU (red) treated cell lines ( n = 3 replicates). (D) Schematic of the four selected SASP inhibitors mechanisms of action: Bindarit is a CCL2 synthesis inhibitor which prevents p65 activation of the CCL2 gene at the promoter region, ISO‐1 is a MIF antagonist, ACT‐1004‐1239 is a CXCR7 antagonist, and Sitagliptin inhibits DPP4 preventing its action of cleaving and inactivating CXCL12 (created with BioRender). Data were analyzed by two‐way ANOVA with Tukey's multiple comparisons test (C). All graphs show mean with error bars depicting standard deviation (ns, p > 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: Treatment with DPP4 inhibitor Sitagliptin (MedChemExpress, Catalog No. HY‐13749) was used to eliminate DPP4‐dependent cleavage and inactivation of CXCL12, which is a ligand of the CXCR7 receptor.

Techniques: Activation Assay, RNA sequencing, Expressing, Standard Deviation

Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or sitagliptin (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001

Journal: Journal of Translational Medicine

Article Title: HIF-1α attenuates ferroptosis-associated dermal fibroblast senescence via modulation of NF-κB–DPP4 signaling

doi: 10.1186/s12967-026-08445-y

Figure Lengend Snippet: Hypoxia-mediated elimination of DPP4 protects HDFs from ferroptosis-associated senescence. (A) Human Protein Atlas database analysis of DPP4 expression across 18 skin cell clusters. (B) DPP4 mRNA expression in human skin from suprapubic (non–sun-exposed) and lower leg (sun-exposed) regions (Human Protein Atlas, https://www.proteinatlas.org ). (C) Quantification of DPP4 IHC staining in sun-exposed and non–sun-exposed skin using a normal human skin tissue array (SKN1001). ( n = 8, 76). (D , E) Flow cytometry of young HDFs treated with erastin (10 µM) or RSL3 (200 nM) for 4 h, washed, and cultured under normoxia or hypoxia for 48 h; quantification of DPP4⁺SPiDER-βGal⁺ cells (Q2 region). ( n = 3 each). (F) qRT-PCR quantification of DPP4 mRNA relative to housekeeping controls. ( n = 3 each). (G , H) Young HDFs treated with erastin or RSL3 for 4 h, washed, and subsequently treated with saxagliptin (50 µM) or sitagliptin (50 µM) under normoxia for 48 h; immunoblotting of COL1A1, COL3A1, MMP-1, MMP-3 and p21. ( n = 3 each). (I) Overexpression of HA-DPP4 or empty vector (3 µg/mL) in young and aged HDFs after ferroptosis induction; immunoblotting of DPP4, COL1A1, COL3A1, MMP-1, MMP-3, and p21. ( n = 3 each). Data are presented as mean ± SD. Quantification of the results is shown * P < 0.05, ** P < 0.01, and *** P < 0.001

Article Snippet: Chemical reagents included doxorubicin (HY-15142), DMOG (HY-15893), Erastin (HY-15763), RSL3 (HY-100218 A), Saxagliptin (HY-10285), Sitagliptin (HY-13749), and recombinant human DPP4 (rhDPP4; HY-N0135), all purchased from MedChemExpress (MCE).

Techniques: Expressing, Immunohistochemistry, Flow Cytometry, Cell Culture, Quantitative RT-PCR, Western Blot, Over Expression, Plasmid Preparation